028 Myeloma in 2026 - What's Coming Next and Why It Matters

Описание: This episode looks ahead to 2026, exploring upcoming myeloma treatments, major research advances, and the topics patients and carers most want to understand.



📌Key Takeaways:




• Powerful new immunotherapy combinations could dramatically change how long treatments work.


• CAR T-cell therapy and bispecific antibodies are moving closer to earlier use in myeloma care.


• Living well with myeloma matters more than ever - from infection risk to quality of life.




For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/



We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/



The Myeloma UK InfoLine is: 0800 980 3332



This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns



 



ABOUT YOUR HOSTS



Dr. Jam Kothari



Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.



 



Dr. Sally Moore



Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.